NT-501 ECT is currently in development for retinal degenerative diseases. NT-501 ECT delivers ciliary neurotrophic factor (CNTF), a human growth factor that preferentially stimulates and protects neural cells, including photoreceptor cells responsible for detecting light in the retina.
Neurotech is conducting multiple clinical studies with NT-501 ECT, including trials in subjects with macular telangectasia (MacTel) and glaucoma.
A total of 184 subjects have been enrolled in three separate Phase 2 studies in the US, with some subjects reaching past 50 months post-implantation.
Neurotech has discontinued the NT-503-3 Phase 2 program.